{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the confidence interval was not estimable because too few participants had worsening assessment after response or death.","groupId":"OG000","lowerLimit":"12.22","upperLimit":"NA","value":"53.29"}]}],"title":"Investigator assessment"},{"categories":[{"measurements":[{"comment":"The median and the upper limit of the confidence interval were not estimable because too few participants had worsening assessment after response or death.","groupId":"OG000","lowerLimit":"27.86","upperLimit":"NA","value":"NA"}]}],"title":"CRC assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Duration of complete response was defined as the time from the first assessment of complete response to the earlier of the date of first worsening assessment after complete response or death due to any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemigatinib 13.5 milligrams (mg) was self-administered once daily (QD) as oral tablets on an intermittent dosing (ID) schedule or continuous dosing (CD) schedule. Participants started pemigatinib 13.5 mg on the ID schedule (i.e., 2 weeks on/1 week off) as per the initial Protocol and on the CD schedule in 21-day cycles following a Protocol amendment.","id":"OG000","title":"Pemigatinib 13.5 mg"}],"paramType":"MEDIAN","populationDescription":"Full Efficacy-Evaluable Population. Only participants with a complete response were analyzed. Confidence intervals were calculated using the Brookmeyer and Crowley's method.","reportingStatus":"POSTED","timeFrame":"up to 2513 days (120 21-day treatment cycles)","title":"Duration of Complete Response","type":"SECONDARY","unitOfMeasure":"months"}